Biogen Inc. (BIIB)
Health Care ยท Biological Products, (No Diagnostic Substances)
Biogen Inc. (BIIB) is listed on Nasdaq, where its shares have traded since September 17, 1991. SentiSense covers Biogen Inc. in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances). Christopher Viehbacher is its chief executive officer. The company reports 7,500 employees, and its corporate website is www.biogen.com.
About Biogen Inc.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 1,022 institutions reported holding BIIB, with 140.6 million shares worth $30.3 billion in aggregate. The largest reported holders were FMR, Vanguard and BlackRock. Of the 5 largest reported holders, all 5 added shares during the quarter.
More on BIIB
- BIIB sentiment: whether news and social coverage of Biogen Inc. leans bullish or bearish, and the stories driving it.
- BIIB ownership: all 1,022 reporting institutions, plus insider and congressional trades.
- BIIB financials: revenue, net income, operating margin and free cash flow by quarter and year.
SentiSense also tracks daily options readings for Biogen Inc.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Biogen Inc. do?
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases.
What sector is BIIB in?
SentiSense classifies Biogen Inc. in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances).
Where does BIIB stock trade?
Biogen Inc. (BIIB) is listed on Nasdaq, where its shares have traded since September 17, 1991.
Who is the CEO of Biogen Inc.?
Christopher Viehbacher is the chief executive officer of Biogen Inc..